ArticleAnnals of the rheumatic diseases2021
Severe COVID-19-associated pneumonia in 3 patients with systemic sclerosis treated with rituximab.
Article in Annals of the rheumatic diseases, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 49 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
49 citing papers in PubMed.
- COVID-19 vaccination of patients with chronic immune-mediated inflammatory disease.Advances in rheumatology (London, England) · 2023Article
- COVID-19 in patients with rheumatological diseases in the Eastern Province of Saudi Arabia.Journal of medicine and life · 2023Observational
- Review of an Anti-CD20 Monoclonal Antibody for the Treatment of Autoimmune Diseases of the Skin.American journal of clinical dermatology · 2023Review
- CovAID: Identification of factors associated with severe COVID-19 in patients with inflammatory rheumatism or autoimmune diseases.Frontiers in medicine · 2023Article
- Systemic sclerosis in the time of COVID-19.The Lancet. Rheumatology · 2022Review
- Severity and mortality of COVID-19 in patients with systemic sclerosis: a Brazilian multicenter study.Seminars in arthritis and rheumatism · 2022Observational
- Pemphigus during the COVID-19 Epidemic: Infection Risk, Vaccine Responses and Management Strategies.Journal of clinical medicine · 2022Review
- The Role of the Multidisciplinary Health Care Team in the Management of Patients with Systemic Sclerosis.Journal of multidisciplinary healthcare · 2022Review
- Open questions on the management of targeted therapies for the treatment of systemic sclerosis-interstitial lung disease: results of a EUSTAR survey based on a systemic literature review.Therapeutic advances in musculoskeletal disease · 2022Review
- Neutralizing monoclonal antibodies against SARS-CoV-2 for COVID-19 pneumonia in a rituximab treated patient with systemic sclerosis-A case report and literature review.Frontiers in medicine · 2022Article
- Psychological Fragility in an Italian Cohort of Systemic Sclerosis Patients During COVID-19 Pandemic Category: Short Communication.Open access rheumatology : research and reviews · 2022Article
- The Robustness of Cellular Immunity Determines the Fate of SARS-CoV-2 Infection.Frontiers in immunology · 2022Review
- Updated recommendations of the German Society for Rheumatology for the care of patients with inflammatory rheumatic diseases in the context of the SARS-CoV-2/COVID-19 pandemic, including recommendations for COVID-19 vaccination.Zeitschrift fur Rheumatologie · 2021Review
- Convalescent plasma therapy in an immunocompromised patient with multiple COVID-19 flares: a case report.Respirology case reports · 2021Article
- Management of thyroid disorders during the COVID-19 outbreak: a position statement from the Thyroid Department of the Brazilian Society of Endocrinology and Metabolism (SBEM).Archives of endocrinology and metabolism · 2021Article
- The Outcome of COVID-19 in Patients with a History of Taking Rituximab: A Narrative Review.Iranian journal of medical sciences · 2021Review
- Protracted severe COVID-19 pneumonia following rituximab treatment: caution needed.Rheumatology international · 2021Review
- Successful treatment of COVID-19 infection with convalescent plasma in B-cell-depleted patients may promote cellular immunity.European journal of immunology · 2021Article
- High-titre convalescent plasma therapy for an immunocompromised patient with systemic lupus erythematosus with protracted SARS-CoV-2 infection.BMJ case reports · 2021Article
- Clearance of the SARS-CoV-2 Virus in an Immunocompromised Patient Mediated by Convalescent Plasma without B-Cell Recovery.International journal of molecular sciences · 2021Article
Corrections and comments
- Commented on by
- Comment on
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
32503849What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.